AndreyPopov/iStock via Getty Images
- Acadia Pharmaceuticals (NASDAQ:ACAD) said on Monday that the U.S. Court of Appeals upheld a December 2023 ruling, confirming the validity of the Nuplazid ‘740 composition of matter patent.
- This affirmation is significant in Acadia’s ongoing legal battle with MSN Laboratories Pvt and MSN Pharmaceuticals.
- The Appeals Court upheld the ruling from Allergan USA v. MSN Laboratories, stating that an earlier claim cannot be invalidated by a later one with the same priority date.
- The decision follows U.S. District Court for the District of Delaware ruling in favor of Acadia on its ‘721 formulation patent for Nuplazid, confirming both infringement and validity against Aurobindo Pharma Limited and other ANDA applicants.
More on Acadia Pharma
- Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview
- ACADIA Pharmaceuticals: Advancing On Several Fronts
- ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript
- Acadia Pharmaceuticals jumps after win in patent suit over Nuplazid
- Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data